These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32234294)

  • 21. Invariant natural killer T cells as sensors and managers of inflammation.
    Van Kaer L; Parekh VV; Wu L
    Trends Immunol; 2013 Feb; 34(2):50-8. PubMed ID: 23017731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human CD4
    Baiu DC; Sharma A; Schehr JL; Basu J; Smith KA; Ohashi M; Johannsen EC; Kenney SC; Gumperz JE
    Immunology; 2024 Aug; 172(4):627-640. PubMed ID: 38736328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
    Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
    Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innate immune control of EBV-infected B cells by invariant natural killer T cells.
    Chung BK; Tsai K; Allan LL; Zheng DJ; Nie JC; Biggs CM; Hasan MR; Kozak FK; van den Elzen P; Priatel JJ; Tan R
    Blood; 2013 Oct; 122(15):2600-8. PubMed ID: 23974196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?
    Venken K; Favreau M; Gaublomme D; Menu E; Vanderkerken K; Elewaut D
    Mol Immunol; 2018 Sep; 101():521-526. PubMed ID: 30153633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognate interaction with iNKT cells expands IL-10-producing B regulatory cells.
    Vomhof-DeKrey EE; Yates J; Hägglöf T; Lanthier P; Amiel E; Veerapen N; Besra GS; Karlsson MC; Leadbetter EA
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12474-9. PubMed ID: 26392556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The in vivo response of invariant natural killer T cells to glycolipid antigens.
    Parekh VV; Lalani S; Van Kaer L
    Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invariant natural killer T cells and their ligands: focus on multiple sclerosis.
    O'Keeffe J; Podbielska M; Hogan EL
    Immunology; 2015 Aug; 145(4):468-75. PubMed ID: 25976210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
    Guan P; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycolipid activators of invariant NKT cells as vaccine adjuvants.
    Kharkwal SS; Arora P; Porcelli SA
    Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids.
    Shimamura M; Yamamura M; Nabeshima T; Kitano N; van den Elzen P; Yesilkaya H; Andrew P; Illarionov P
    Sci Rep; 2017 Aug; 7(1):9703. PubMed ID: 28852174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface.
    Brennan PJ; Cheng TY; Pellicci DG; Watts GFM; Veerapen N; Young DC; Rossjohn J; Besra GS; Godfrey DI; Brenner MB; Moody DB
    Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8348-8353. PubMed ID: 28716901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
    Gerth E; Mattner J
    Front Immunol; 2019; 10():1449. PubMed ID: 31293596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.
    Yang G; Richt JA; Driver JP
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29280974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human invariant natural killer T cells: implications for immunotherapy.
    Takahashi T; Kurokawa M
    Int J Hematol; 2009 Sep; 90(2):137-142. PubMed ID: 19639273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.
    Kim S; Lalani S; Parekh VV; Wu L; Van Kaer L
    Expert Rev Vaccines; 2008 Dec; 7(10):1519-32. PubMed ID: 19053208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes.
    Albu DI; VanValkenburgh J; Morin N; Califano D; Jenkins NA; Copeland NG; Liu P; Avram D
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6211-6. PubMed ID: 21444811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes.
    Arora P; Kharkwal SS; Ng TW; Kunnath-Velayudhan S; Saini NK; Johndrow CT; Chang YT; Besra GS; Porcelli SA
    Chem Phys Lipids; 2015 Oct; 191():75-83. PubMed ID: 26306469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.
    Van Kaer L; Parekh VV; Wu L
    Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria.
    Kinjo Y; Illarionov P; Vela JL; Pei B; Girardi E; Li X; Li Y; Imamura M; Kaneko Y; Okawara A; Miyazaki Y; Gómez-Velasco A; Rogers P; Dahesh S; Uchiyama S; Khurana A; Kawahara K; Yesilkaya H; Andrew PW; Wong CH; Kawakami K; Nizet V; Besra GS; Tsuji M; Zajonc DM; Kronenberg M
    Nat Immunol; 2011 Sep; 12(10):966-74. PubMed ID: 21892173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.